The Markey Cancer Center (MCC), a dedicated matrix cancer center established as an integral part of the University of Kentucky (UK) and the UK Healthcare enterprise, has undergone dramatic expansion in recent years under the leadership of MCC Director Dr. B. Mark Evers. At this point in the center's development, the MCC seeks support through the National Cancer Institute (NCI) Cancer Center Support Grant to capitalize on this momentum and to drive a measurable reduction in cancer mortality in Kentucky, particularly Appalachian Kentucky, through a comprehensive program of cancer research, prevention, and patient care. The need for NCI Cancer Center designation is particularly acute in a state that leads the nation across numerous cancer indicators, including the highest rate of cancer deaths in the nation. Situated on a campus with all six health professions colleges in proximity to each other, the MCC offers a history of rich transdisciplinary collaboration, an outstanding program of cancer prevention and control that has produced seminal work in Appalachian Kentucky, nationally acclaimed basic research programs in cancer biology and DNA repair and oxidative stress, and a translational therapeutics program complemented by a top five College of Pharmacy. These strengths have coalesced in MCC's four thematic research programs: Cancer Cell Biology and Signaling;Cancer Prevention and Control;Drug Discovery, Delivery and Translational Therapeutics;and Redox Injury and Repair. Currently, the MCC's 108 Research and Associate Research members hold appointments in 24 departments in 7 colleges across the university (25 new faculty were recruited in the last 3 years). MCC members hold grants for 144 research projects funded in the annual composite (direct + indirect) amount of more than $30.5 million, of which over $11.3 million (37%) comes from the NCI. Accrual to therapeutic clinical trials has increased over 130% in three years, and MCC assignable space has increased 40%, including a doubling of state-of-the-art research space. In addition, six shared resources facilitate cutting-edge research by providing a robust infrastructure for specialized expertise and advanced methods. They include: Biospecimen and Tissue Procurement;Biostatistics;Cancer Research Informatics;Clinical Research and Data Management;Flow Cytometry and Cell Sorting;and Free Radical Biology in Cancer. The MCC is currently well positioned to take on new challenges and to continue to evolve in key strategic directions that take maximum advantage of these strengths.

Public Health Relevance

As a state with the second highest all-site cancer Incidence rate and the highest rate of cancer deaths in the United States, Kentucky suffers from particularly intractable cancer health challenges. The Markey Cancer Center seeks support to further develop its capacities in cutting-edge science to accelerate bench to bedside translational outcomes, which will reduce this serious health disparity and significantly impact our patients, our state, and the nation through cancer prevention, patient care, and research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA177558-01
Application #
8551960
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
2013-07-08
Project End
2018-06-30
Budget Start
2013-07-08
Budget End
2014-06-30
Support Year
1
Fiscal Year
2013
Total Cost
$1,402,503
Indirect Cost
$467,501
Name
University of Kentucky
Department
Surgery
Type
Schools of Medicine
DUNS #
939017877
City
Lexington
State
KY
Country
United States
Zip Code
40506
Starr, Marlene E; Steele, Allison M; Cohen, Donald A et al. (2016) Short-Term Dietary Restriction Rescues Mice From Lethal Abdominal Sepsis and Endotoxemia and Reduces the Inflammatory/Coagulant Potential of Adipose Tissue. Crit Care Med 44:e509-19
Sharma, Ashwani; Haque, Farzin; Pi, Fengmei et al. (2016) Controllable self-assembly of RNA dendrimers. Nanomedicine 12:835-44
Li, Hui; Zhang, Kaiming; Pi, Fengmei et al. (2016) Controllable Self-Assembly of RNA Tetrahedrons with Precise Shape and Size for Cancer Targeting. Adv Mater 28:7501-7
Jiang, Kai; Liu, Yajuan; Fan, Junkai et al. (2016) PI(4)P Promotes Phosphorylation and Conformational Change of Smoothened through Interaction with Its C-terminal Tail. PLoS Biol 14:e1002375
Klimyte, Edita M; Smith, Stacy E; Oreste, Pasqua et al. (2016) Inhibition of Human Metapneumovirus Binding to Heparan Sulfate Blocks Infection in Human Lung Cells and Airway Tissues. J Virol 90:9237-50
Butterfield, D Allan; Palmieri, Erika M; Castegna, Alessandra (2016) Clinical implications from proteomic studies in neurodegenerative diseases: lessons from mitochondrial proteins. Expert Rev Proteomics 13:259-74
Stewart, Rachel L; West, Dava; Wang, Chi et al. (2016) Elevated integrin α6β4 expression is associated with venous invasion and decreased overall survival in non-small cell lung cancer. Hum Pathol 54:174-83
Stewart, Rachel L; Carpenter, Brittany L; West, Dava S et al. (2016) S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide. Oncotarget 7:34630-42
Khisamutdinov, Emil F; Jasinski, Daniel L; Li, Hui et al. (2016) Fabrication of RNA 3D Nanoprisms for Loading and Protection of Small RNAs and Model Drugs. Adv Mater 28:10079-10087
Li, Jing; Song, Jun; Weiss, Heidi L et al. (2016) Activation of AMPK Stimulates Neurotensin Secretion in Neuroendocrine Cells. Mol Endocrinol 30:26-36

Showing the most recent 10 out of 177 publications